Novavax’s 2024-2025 COVID-19 Vaccine Receives EUA for Use in the U.S.

Pallavi Madhiraju- September 1, 2024 0

Novavax, Inc. (Nasdaq: NVAX), a leading company in protein-based vaccines, has announced that its latest COVID-19 vaccine, the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705), ... Read More

New study suggests COVID-19 vaccines may have contributed to excess deaths in Western countries

Pallavi Madhiraju- June 6, 2024 0

A recent study published in BMJ Public Health has sparked controversy by suggesting that COVID-19 vaccines may have contributed to a rise in excess deaths ... Read More

AstraZeneca withdraws COVID-19 vaccine amid legal challenges and commercial decisions

Pallavi Madhiraju- May 8, 2024 0

In a significant development, UK-based pharmaceutical giant AstraZeneca has announced the global withdrawal of its COVID-19 vaccine, known as Covishield in India and Vaxzevria in ... Read More

Pfizer withdraws emergency use application for COVID-19 vaccine in India

pharmanewsdaily- February 5, 2021 0

US pharmaceutical giant Pfizer has withdrawn its application for emergency use authorization of its BNT162b2 COVID-19 vaccine in India. This decision comes after a series ... Read More

UAE grants emergency use authorization for Sputnik V Covid-19 vaccine

pharmanewsdaily- January 23, 2021 0

The Russian Direct Investment Fund (RDIF) has announced that the UAE Ministry of Health and Prevention (MOHAP) has granted emergency use authorization for the Sputnik ... Read More

Switzerland approves Pfizer-BioNTech Covid-19 vaccine for emergency use, marking global first

pharmanewsdaily- December 20, 2020 0

Switzerland has become the first country to grant full approval for the Pfizer-BioNTech BNT162b2 Covid-19 vaccine, making a significant move in the global race against ... Read More

UK grants emergency authorization for Pfizer and BioNTech’s BNT162b2 Covid-19 vaccine

pharmanewsdaily- December 2, 2020 0

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted emergency use authorization (EUA) for the BNT162b2 Covid-19 vaccine candidate, developed by Pfizer and ... Read More